Livzon Pharmaceutical Group

Livzon Pharmaceutical Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Livzon Pharmaceutical Group (000513.SZ) as of Nov 1, 2026 is 128.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 116.86 % — a change of 10.17% (higher).

FCF Conversion

128.75 %

YoY

10.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Livzon Pharmaceutical Group is 2025 128.75 % . FCF Conversion Rate (FCF/EBITDA) of Livzon Pharmaceutical Group was 2024 116.86 % . It decreases by 10.17% higher compared to the previous year.

The Livzon Pharmaceutical Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
73.29 CNY
Jan 1, 2019
105.09 CNY
Jan 1, 2020
88.27 CNY
Jan 1, 2021
33.41 CNY
Jan 1, 2022
95.97 CNY
Jan 1, 2023
124.30 CNY
Jan 1, 2024
116.86 CNY
Jan 1, 2025
128.75 CNY
The Livzon Pharmaceutical Group FCF Conversion history
YEARFCF ConversionYoY
128.75 %+10.17%
116.86 %-5.99%
124.30 %+29.52%
95.97 %+187.27%
33.41 %-62.15%
88.27 %-16.00%
105.09 %+43.38%
73.29 %+217.69%
23.07 %-80.13%
116.12 %+60.43%
72.38 %+619.92%
10.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Livzon Pharmaceutical Group Stock analysis

What does Livzon Pharmaceutical Group do? Livzon Pharmaceutical Group Inc is a large Chinese company specializing in the development and marketing of pharmaceutical products. It was founded in 1985 and is headquartered in Zhuhai, a city in the southern Chinese province of Guangdong. Livzon is now one of the largest companies in the Chinese pharmaceutical industry and also has a good international reputation. Business model and divisions: The company's business model is diverse and includes research and development, production and distribution of bio-pharmaceuticals, active pharmaceutical ingredients (APIs), generics, traditional Chinese medicines, and diagnostics. Livzon is divided into various divisions, including the bio-pharmaceutical division, the generics division, and the traditional Chinese medicine division. These divisions have different focuses and products. Bio-pharmaceuticals: The bio-pharmaceutical division focuses on the research and development of biopharmaceutical products based on biological processes. The goal is to develop new treatment options for serious diseases such as cancer, autoimmune diseases, or infectious diseases. The most well-known products include the cancer drug Lyophilized Powder Injection and the treatment for autoimmune diseases Levamisole Hydrochloride. Generics: In the generics division, Livzon produces patent-free drugs that offer an alternative to expensive original medications. The company places special emphasis on testing and certifying the quality of its products. Livzon has an extensive range of generics with active ingredients for various diseases, such as hypertension, diabetes, and gastrointestinal diseases. Traditional Chinese medicine: Livzon is one of the few modern pharmaceutical companies specializing in the development and marketing of traditional Chinese medicines. Plant extracts and components derived from animal products are used for therapeutic purposes. The most well-known products include Yiganerjing Cream, a remedy for eczema, and Huoluo Oil, used for joint pain. Products: Livzon has introduced a variety of products to the market in recent years that have gained international recognition. Particularly notable are the products in the bio-pharmaceutical division, which are used in cancer therapy. Additionally, generics and traditional Chinese medicines are important components of the product portfolio. As one of the leading companies in the Chinese pharmaceutical industry, Livzon strives to meet the needs of its customers and continuously expand its offerings. Furthermore, the company is investing heavily in expanding its research and development department to develop innovative products that better meet the needs of patients. Livzon Pharmaceutical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Livzon Pharmaceutical Group stock

FCF Conversion Rate (FCF/EBITDA) of Livzon Pharmaceutical Group is 128.75 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Livzon Pharmaceutical Group changed from 116.86 % to 128.75 %, representing a 10.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Livzon Pharmaceutical Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Livzon Pharmaceutical Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Livzon Pharmaceutical Group

All Key Metrics — Livzon Pharmaceutical Group